Ladybon (Tibolone)

• Ladybon (tibolone) is used within hormone replacement therapy to manage conditions related to estrogen deficiency and menopause.
• Menopausal symptoms: reduces hot flashes, night sweats and mood swings.
• Estrogen deficiency: restores hormonal balance after menopause.
• Prevention of osteoporosis: helps maintain bone mineral density in post‑menopausal women.

• Tibolone is metabolized into three active compounds that bind to estrogen, progesterone and androgen receptors. The estrogenic metabolites alleviate vasomotor and urogenital symptoms, the progestogenic activity counteracts endometrial stimulation, and the androgenic effects contribute to bone maintenance and libido improvement.

Tibolone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Nausea or gastrointestinal discomfort.
• Breast tenderness or swelling.
• Mood changes or irritability.
• Weight gain or fluid retention.

Serious or Rare Side Effects

• Venous thromboembolism: risk of deep vein thrombosis or pulmonary embolism.
• Stroke or cerebrovascular events.
• Liver dysfunction: elevated enzymes or hepatitis.
• Breast cancer: potential increased risk with long‑term use.
• Severe allergic reactions: rash, swelling, or anaphylaxis.

• Before initiating tibolone therapy, consider the following safety measures.
• Monitor liver function: assess hepatic enzymes periodically.
• Assess cardiovascular risk: evaluate history of thrombosis or stroke.
• Screen for breast disease: perform regular clinical examinations.
• Avoid use in pregnancy: contraindicated in women who are pregnant or may become pregnant.
• Do not use in active malignancy: especially estrogen‑dependent cancers.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Tibolone can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Anticoagulants (e.g., warfarin): may enhance bleeding risk.
• Hormonal contraceptives: tibolone can diminish contraceptive effectiveness.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase tibolone plasma levels.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower tibolone exposure.
• Selective serotonin reuptake inhibitors (SSRIs): potential additive effect on mood.
• Antihypertensive agents: monitor blood pressure for additive hypotensive effect.